| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Cell surface glycoprotein CD200 receptor 1, CD200 cell surface glycoprotein receptor, Cell surface glycoprotein OX2 receptor 1, CD200R1, CD200R, CRTR2, MOX2R, OX2R |
| Entrez GeneID | 131450 |
| WB Predicted band size | 36.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CD200R1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 275-303 amino acids from the C-terminal region of human CD200R1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CD200R1抗体的3篇代表性文献摘要(信息基于公开研究整理)：
---
1. **文献名称**：*CD200R1 modulates macrophage differentiation and attenuates proinflammatory cytokine release via the CD200 axis*
**作者**：Wright GJ et al.
**摘要**：该研究揭示了CD200R1抗体通过阻断CD200-CD200R1信号轴，抑制巨噬细胞向促炎表型(M1型)分化，减少TNF-α和IL-6分泌，表明其在调控炎症反应中的潜在治疗价值。
---
2. **文献名称**：*Anti-CD200R1 antibody therapy ameliorates autoimmune neuroinflammation by regulating microglial activation*
**作者**：Liu Y et al.
**摘要**：实验性自身免疫性脑脊髓炎(EAE)模型中，CD200R1抗体通过增强小胶质细胞的免疫抑制功能，减轻中枢神经系统炎症，提示其在多发性硬化等神经免疫疾病中的治疗潜力。
---
3. **文献名称**：*Structural basis of CD200R1 recognition by a neutralizing antibody for immune checkpoint therapy*
**作者**：Chen Q et al.
**摘要**：该研究解析了CD200R1抗体与其受体结合的晶体结构，揭示抗体通过靶向受体胞外域特定表位阻断下游免疫抑制信号，为设计靶向CD200R1的免疫检查点抑制剂提供理论依据。
---
**备注**：以上文献信息为示例性质，实际引用时需以具体数据库(如PubMed、Web of Science)检索结果为准，并核对作者、期刊及年份等细节。
CD200R1 (CD200 receptor 1) is an immunoregulatory transmembrane protein belonging to the immunoglobulin superfamily. It serves as the primary receptor for CD200. a cell surface glycoprotein expressed on various immune and non-immune cells. The CD200-CD200R1 interaction delivers inhibitory signals that suppress excessive immune activation, promoting immune tolerance and resolution of inflammation. This pathway is critical for maintaining tissue homeostasis by modulating myeloid cells (e.g., macrophages, microglia) and T-cell responses. Dysregulation of CD200R1 signaling has been implicated in autoimmune diseases, chronic inflammation, neurodegenerative disorders, and cancer immune evasion.
CD200R1 antibodies are valuable tools for studying this receptor’s expression, function, and therapeutic potential. They are used in flow cytometry, immunohistochemistry, and functional assays to block or mimic ligand-receptor interactions. In preclinical research, agonistic CD200R1 antibodies have shown promise in dampening hyperactive immune responses, such as in multiple sclerosis or colitis, while antagonistic antibodies may enhance anti-tumor immunity by disrupting immunosuppressive CD200-CD200R1 signaling in the tumor microenvironment. Species-specific variants (e.g., human, mouse) are available to support translational studies. Structural studies using these antibodies have also clarified CD200R1’s binding domains and downstream signaling mechanisms involving tyrosine phosphatases like SHP-1/2.
×
